Read the Latest News

Patients in Los Angeles or New York City Needed for Clinical Study - Comparative Study of Women Considering or Currently Receiving Botox© Injections for TMJ Pain

Are you a woman with "TMJ" pain in facial muscles, who has either: a. recently had Botox© injections for your pain or b. not had Botox© for your pain but has thought about such treatment? If either is true for you, you may qualify for an observational research study centrally administered by the NYU College of Dentistry. It is funded by the National Institutes of Health (NIH). The purpose of this study is to understand potential health risks that may be caused by treating "TMJ pain" with Botox© injections.

Why Head and Face Pain Cause More Suffering

Hate headaches? The distress you feel is not all in your -- well, head. People consistently rate pain of the head, face, eyeballs, ears and teeth as more disruptive, and more emotionally draining, than pain elsewhere in the body.

Migraine and Coronary Artery Disease: A Genetic Connection

There has long been as association between migraine headaches and vascular (blood vessel) dysfunction of some kind, underscored by epidemiological studies and other research. New evidence for a genetic connection now comes from the analysis of several large data sets of each condition based on Genome Wide Association Studies (GWAS).

Patients with Chronic Migraine More Likely to Suffer from TMD

In a recent study, researchers found that patients with chronic migraines which usually occur for more than 15 days a month are likely to experience three times more severe symptoms of Temporomandibular disorder (TMD) than patients with an episodic migraine.

Are you a TMD patient with Tinnitus?

It's a ringing sound, a buzzing, a hiss.... It can be soft or loud, intermittent or present all the time, affecting one ear or both. In whatever way it affects you, it's damned annoying, unpleasant, distracting. Indeed, it is considered the worst problem affecting human beings after pain and dizziness.

NIDCR Funds Consortium for Developing Dental and Orofacial Tissue Regeneration Therapies

  • May 31, 2017

The National Institute of Dental and Craniofacial Research (NIDCR) announced two new cooperative agreements aimed at developing resources and strategies for regenerating dental, oral, and craniofacial (DOC) tissues that have been damaged by disease or injury. Totaling $24 million over three years, these awards support the development of two Resource Centers as part of the NIDCR's Dental, Oral, and Craniofacial Tissue Regeneration Consortium (DOCTRC), an initiative designed to shepherd new therapies through pre-clinical studies and into human clinical trials. The ultimate goal is to develop strategies and devices that could help repair or regenerate damaged DOC tissues, including craniofacial bone, muscle and blood vessels, nerves, teeth, and salivary glands.

"By establishing this research consortium, NIDCR seeks to lead national efforts to accelerate the translation of promising DOC regenerative medicine therapies into the clinic," said NIDCR Director Martha J. Somerman, D.D.S., Ph.D. "DOCTRC is designed as a model for optimizing translation of scientific advances in this field."

To date, few DOC therapies based on regenerative medicine have been commercialized and reached the clinic. A careful analysis of NIDCR's research portfolio identified barriers to the process, and the DOCTRC was established to address them and build on the strength of existing research, using approaches such as:

  • Enhanced focus on clinical needs and involvement of practicing clinicians to inform the design of new therapies.
  • Development of approaches to generate multi-tissue composites rather than using a single tissue type.
  • Targeted translational research and early regulatory guidance.
  • Coordination among investigators and industry to develop, validate, and commercialize new tools and technologies.

DOCTRC is composed of three Stages. Stage 1, a one-year planning phase, was successfully completed in 2016. Among proposals submitted for Stage 2, two groups received awards to develop the Resource Centers over the next three years. The Centers will bring together clinical, scientific, industrial, and regulatory experts to develop an infrastructure to deliver high-quality support to Interdisciplinary Translational Projects to be launched during Stages 2 and 3. This support will entail development of standard assays, procedures, and study models to ensure that investigators can uniformly and reliably validate the technologies.

In Stage 3, the Resource Centers will collaborate with both internal and external investigators to move projects to the point of filing Investigational New Drug or Investigational Device Exemption (IND/IDE) applications with the U.S. Food and Drug Administration and launching human clinical trials.

"The DOCTRC consortium aims to streamline translation of dental, oral, and craniofacial regenerative therapies by leveraging multidisciplinary expertise to establish a systematic and uniform research process," said Nadya Lumelsky, Ph.D., Program Director of NIDCR's Tissue Engineering and Regenerative Medicine Research Program. "By establishing two national cores to support the regenerative medicine research community, DOCTRC represents a new paradigm in translational medicine."

The following RCs will be funded for up to three years:

Additional articles related to this announcement:
School of Dentistry Leads Major New Regenerative Medicine Center Funded by NIH

UCSF to Lead Resource Team for Craniofacial, Oral and Dental Tissue Regeneration

TMJ Disorders


Login or Register to add Comment

In Treating TMJ

To view or order a free booklet about TMJ Disorders, visit the National Institutes of Health website.

National Institutes of Health
National Institute of Dental and Craniofacial Research
Office of Research on Women's Health